CN105707856B - 具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法 - Google Patents
具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法 Download PDFInfo
- Publication number
- CN105707856B CN105707856B CN201610071936.2A CN201610071936A CN105707856B CN 105707856 B CN105707856 B CN 105707856B CN 201610071936 A CN201610071936 A CN 201610071936A CN 105707856 B CN105707856 B CN 105707856B
- Authority
- CN
- China
- Prior art keywords
- lee
- fruit
- accounts
- extract
- microcapsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 239000003094 microcapsule Substances 0.000 title claims abstract description 46
- 235000021028 berry Nutrition 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 108010093894 Xanthine oxidase Proteins 0.000 title claims abstract description 23
- 102100033220 Xanthine oxidase Human genes 0.000 title claims abstract description 23
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 121
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 40
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 40
- 239000011347 resin Substances 0.000 claims abstract description 16
- 229920005989 resin Polymers 0.000 claims abstract description 16
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 16
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims abstract description 14
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 claims abstract description 14
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000008777 kaempferol Nutrition 0.000 claims abstract description 7
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 7
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000000746 purification Methods 0.000 claims abstract description 7
- 235000005875 quercetin Nutrition 0.000 claims abstract description 7
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 claims abstract description 7
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 6
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims abstract description 6
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 6
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 6
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 6
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000007743 myricetin Nutrition 0.000 claims abstract description 6
- 229940116852 myricetin Drugs 0.000 claims abstract description 6
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000002989 phenols Chemical class 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 239000000287 crude extract Substances 0.000 claims description 42
- 235000019441 ethanol Nutrition 0.000 claims description 36
- 108010010803 Gelatin Proteins 0.000 claims description 27
- 229920000159 gelatin Polymers 0.000 claims description 27
- 239000008273 gelatin Substances 0.000 claims description 27
- 235000019322 gelatine Nutrition 0.000 claims description 27
- 235000011852 gelatine desserts Nutrition 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 17
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 12
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000011162 core material Substances 0.000 claims description 9
- 238000005354 coacervation Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 6
- 238000003795 desorption Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 241001446187 Kermes Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 claims description 3
- 235000021018 plums Nutrition 0.000 claims description 2
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract description 6
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract description 6
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 6
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract description 6
- 235000005493 rutin Nutrition 0.000 abstract description 6
- 229960004555 rutoside Drugs 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 8
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 8
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 240000005049 Prunus salicina Species 0.000 description 1
- 235000012904 Prunus salicina Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法。李果经超声波‑微波分阶段联合提取、大孔树脂纯化、微胶囊化、真空冷冻干燥制备得李果提取物微胶囊;所述的李果提取物微胶囊含有20~50 wt%李果总酚;其中,结合态多酚占2~8 wt%,杨梅素占1~10 wt%,芦丁占1~10 wt%,檞皮素占0.2~1 wt%,山奈酚占0.1~1 wt%,阿魏酸占0.05~0.5 wt%,芥子酸占0.1~0.8 wt%。本发明的李果提取物微胶囊药效明显,制备方法简单,适宜规模化生产,且具有良好的加工贮藏稳定性,可为降尿酸功能营养食品和药品提供了一种新的原料来源。
Description
技术领域
本发明属于果蔬深加工技术领域,具体涉及一种具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法。
背景技术
高尿酸血症及痛风是当今社会的常见病、多发病,至今无法根治,研究表明长期高尿酸血症与高血压、糖尿病、冠心病、肾衰竭等密切相关。黄嘌呤氧化酶(xanthineoxidase,XOD)是介导尿酸生成的重要酶,能催化黄嘌呤和次黄嘌呤的氧化生成尿酸,同时产生过氧化物自由基。黄嘌呤氧化酶抑制剂可通过抑制黄嘌呤氧化酶的活性,减少黄嘌呤及次黄嘌呤向尿酸盐的转化,从根本上减少尿酸的生成,从而达到治疗痛风的目的。在临床上抑制黄嘌呤氧化酶的药物包括别嘌呤醇、非布司他等,这些西药治疗虽然见效快,但副作用大,使其应用受到明显限制。如别嘌呤醇用后,病人会引起发热、腹痛、腹泻、过敏性皮疹、白细胞及血小板减少,甚至有肝功能损害等副作用。因此寻找新的低毒、高效的黄嘌呤氧化酶抑制剂显得尤为重要。天然产物来源的黄嘌呤氧化酶抑制剂毒性小,安全性高,引起了广泛关注。
许多文献已公开各种天然产物来源的黄嘌呤氧化酶抑制剂,如中药材夏枯草提取物(CN104997843)、中药组合物(CN1698858、CN102205083、CN101879193)、花生四烯酸(CN102133214)、山药、生姜和蒜等蔬菜提取物(CN102106516)、白果仁(CN103893225)、侧柏叶多酚(CN105055463)、秋刀鱼美拉德肽(CN104673865)等,然而目前尚未见以李果实提取物为原料的黄嘌呤氧化酶抑制剂或降尿酸组合物。此外,大部分天然产物来源的黄嘌呤氧化酶抑制剂主要有效成分主要是多酚、黄酮类化合物、活性肽等活性物质,在潮湿、高温、阳光等环境条件下极易发生氧化、聚合等反应,从而影响其贮藏稳定性,限制它们的应用范围,目前公开的文献中大部分未考虑天然黄嘌呤氧化酶抑制剂的加工贮藏稳定性。
李(Prunus salicina Lindl.),是蔷薇科李属植物,是人们最喜欢的水果之一,在福建、广东等中国许多省市及世界各地均有栽培,为重要温带果树之一。目前李果已报道具有抗氧化,促进胃酸和胃消化酶的分泌等功效,但关于李果在抑制黄嘌呤氧化酶和降尿酸方面尚未见报道。
发明内容
本发明的目的在于针对现有技术的不足,提供一种具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法。本发明的制备方法简单、高效;所制得的李果提取物微胶囊活性成分含量高,抑制黄嘌呤氧化酶功效明显,毒副作用小、制备工艺简单、加工贮藏性能好。
为实现上述目的,本发明采用如下技术方案:
一种具有抑制黄嘌呤氧化酶的李果提取物微胶囊,含有20~50 wt%李果总酚;其中,结合态多酚占2~8 wt %,杨梅素占1~10 wt %,芦丁占1~10 wt %,檞皮素占0.2~1wt %,山奈酚占0.1~1 wt %,阿魏酸占0.05~0.5 wt %,芥子酸占0.1~0.8 wt %。
一种制备如上所述的李果提取物微胶囊的方法:将新鲜李果经预处理制得李果粉,然后经超声波-微波分阶段联合提取得到李果粗提液,再经真空浓缩、大孔树脂纯化得到李果多酚提取物,最后经微胶囊化、真空冷冻干燥制备得到李果提取物微胶囊。
具体制备步骤为:
1)预处理:挑选七八成熟的新鲜李果,经纯净水清洗,去核,切片,50℃热泵干燥至水份含量小于15wt%,再将干李果片粉碎至粒径小于2mm以下,制得李果粉;
2)李果粗提液的制备:李果粉先用超声波提取,以40~80 %(v/v)乙醇溶液作为提取溶剂,提取温度为50℃,李果粉:乙醇=1g:15mL,超声波功率为100~400W,提取时间为20~60min,100目筛过滤得李果粗提液Ⅰ;滤渣再用微波萃取,微波萃取参数为:滤渣中加入滤渣质量10~20倍体积的60-80%(v/v)乙醇溶液,在微波功率400-600W下处理5-8min,采用间断微波处理,微波40s,暂停20s,微波萃取后100目筛过滤得李果粗提液Ⅱ;合并李果粗提液Ⅰ和李果粗提液Ⅱ得到李果粗提液;
3)李果多酚提取物的制备:李果粗提液经40℃真空浓缩去除乙醇,真空度为0.01MPa~0.06MPa;再经AB-8大孔树脂纯化李果提取液,蒸馏水洗树脂,80%(v/v)乙醇溶液解吸洗脱,洗脱液40℃真空浓缩,真空冷冻干燥制备得李果多酚提取物;
4)微胶囊化:以明胶和羧甲基纤维素为复合壁材,以李果多酚提取物为芯材,采用复凝聚法制备李果多酚微胶囊;芯材与壁材的质量比为l:1~3,明胶与羧甲基纤维素的质量比为4~6:1;具体为:将2~4wt%明胶水溶液在50℃热水浴中以1500r/min转速搅拌溶解15min,将乙醇溶解后的李果多酚提取物以1500r/min转速边搅拌边加入至明胶溶液中,再将羧甲基纤维素用水溶解后缓慢加入;用10%(v/v)冰醋酸调节pH值至4.5,在45℃下恒温反应20min,于冰水浴中搅拌冷却至10℃以下,加入37%(v/v)甲醛溶液固化15min,用10wt%NaOH溶液调pH 8~9,固化l h,抽滤、洗涤至中性,再抽滤,真空冷冻干燥后即得李果提取物微胶囊。
一种如上所述的具有抑制黄嘌呤氧化酶的李果提取物微胶囊在制备降尿酸功能营养食品或辅助治疗高尿酸血症及痛风的药物中的应用。
本发明所述的李果为芙蓉李、胭脂李的一种;或其副产物(小果、异形果等)。
本发明的显著优点在于:
(1)本发明从李果分离提取出天然、副作物小的黄嘌呤氧化酶抑制剂;该李果提取物微胶囊药效明显,制备方法简单,适宜规模化生产,为降尿酸功能营养食品和药品提供了一种新的天然原料来源;
(2)本发明利用复凝聚法制备李果黄嘌呤氧化酶抑制剂微胶囊,提高李果黄嘌呤氧化酶抑制剂贮藏稳定性,拓宽其应用范围;本发明提供的李果提取物微胶囊,其主要活性物质主要是酚类物质,其中游离态多酚占80%以上,容易受高温、高湿等不利环境影响而遭到破坏,采用操作简单、反应条件温和的复凝聚法制备李果提取物微胶囊,既可减少功能因子在加工或贮藏过程中的损失,又能减少活性物质在人体胃肠消化过程中受胃酸、胃酶的破坏。
具体实施方式
一种具有抑制黄嘌呤氧化酶的李果提取物微胶囊,含有20~50 wt%李果总酚;其中,结合态多酚占2~8 wt %,杨梅素占1~10 wt %,芦丁占1~10 wt %,檞皮素占0.2~1wt %,山奈酚占0.1~1 wt %,阿魏酸占0.05~0.5 wt %,芥子酸占0.1~0.8 wt %。
一种制备如上所述的李果提取物微胶囊的方法:将新鲜李果经预处理制得李果粉,然后经超声波-微波分阶段联合提取得到李果粗提液,再经真空浓缩、大孔树脂纯化得到李果多酚提取物,最后经微胶囊化、真空冷冻干燥制备得到李果提取物微胶囊。
具体制备步骤为:
1)预处理:挑选七八成熟的新鲜李果,经纯净水清洗,去核,切片,50℃热泵干燥至水份含量小于15wt%,再将干李果片粉碎至粒径小于2mm以下,制得李果粉;
2)李果粗提液的制备:李果粉先用超声波提取,以40~80 %(v/v)乙醇溶液作为提取溶剂,提取温度为50℃,李果粉:乙醇=1g:15mL,超声波功率为100~400W,提取时间为20~60min,100目筛过滤得李果粗提液Ⅰ;滤渣再用微波萃取,微波萃取参数为:滤渣中加入滤渣质量10~20倍体积的60-80%(v/v)乙醇溶液,在微波功率400-600W下处理5-8min,采用间断微波处理,微波40s,暂停20s,微波萃取后100目筛过滤得李果粗提液Ⅱ;合并李果粗提液Ⅰ和李果粗提液Ⅱ得到李果粗提液;
3)李果多酚提取物的制备:李果粗提液经40℃真空浓缩去除乙醇,真空度为0.01MPa~0.06MPa;再经AB-8大孔树脂纯化李果提取液,蒸馏水洗树脂,80%(v/v)乙醇溶液解吸洗脱,洗脱液40℃真空浓缩,真空冷冻干燥制备得李果多酚提取物;
4)微胶囊化:以明胶和羧甲基纤维素为复合壁材,以李果多酚提取物为芯材,采用复凝聚法制备李果多酚微胶囊;芯材与壁材的质量比为l:1~3,明胶与羧甲基纤维素的质量比为4~6:1;具体为:将2~4wt%明胶水溶液在50℃热水浴中以1500r/min转速搅拌溶解15min,将乙醇溶解后的李果多酚提取物以1500r/min转速边搅拌边加入至明胶溶液中,再将羧甲基纤维素用水溶解后缓慢加入;用10%(v/v)冰醋酸调节pH值至4.5,在45℃下恒温反应20min,于冰水浴中搅拌冷却至10℃以下,加入37%(v/v)甲醛溶液固化15min,用10wt%NaOH溶液调pH 8~9,固化l h,抽滤、洗涤至中性,再抽滤,真空冷冻干燥后即得李果提取物微胶囊。
为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是本发明不仅限于此。
实施例1
李果提取物微胶囊的制备方法为:
(1)挑选七八成熟的新鲜芙蓉李果实,经干净水清洗,去核,切片,50℃热泵干燥至水份含量14%,再将干李果片粉碎至粒径小于2mm以下;
(2)李果粉先用超声波提取,以80%(v/v)乙醇作为提取溶剂,提取温度为50℃,李果粉:乙醇=1g:15mL,超声波功率为400W,提取时间为20min,100目筛过滤得李果粗提液Ⅰ,滤渣再用微波萃取;微波萃取参数为:滤渣中加入滤渣质量20倍体积的60%(v/v)乙醇,在微波功率400W下处理8min,采用间断微波处理,微波40s,暂停20s,微波萃取后100目筛过滤得李果粗提液Ⅱ;合并李果粗提液Ⅰ和李果粗提液Ⅱ得到李果粗提液;
(3)李果粗提液经40℃真空浓缩去除乙醇,真空度为0.03MPa;再经AB-8大孔树脂纯化李果提取液,蒸馏水洗树脂,80%(v/v)乙醇溶液解吸洗脱,洗脱液40℃真空浓缩至原洗脱液的50%以下,真空冷冻干燥制备得李果多酚提取物;
(4)以明胶和羧甲基纤维素(CMC)为壁材,采用复凝聚法制备李果多酚微胶囊;将明胶加入水中,在50℃热水浴中以1500r/min转速搅拌15min,制得2wt%的明胶溶液;称取李果多酚提取物后,乙醇溶解,以1500r/min转速边搅拌边加入至明胶溶液中,再将羧甲基纤维素热水溶解缓慢加入,芯材:壁材=l:3,明胶与羧甲基纤维素质量比为4:1;用10%(v/v)冰醋酸调节pH值至4.5,在45℃下恒温反应20min,于冰水浴中搅拌冷却至10℃以下,加入37%(v/v)甲醛溶液固化15min ,用10wt%NaOH溶液调pH 9,固化l h,抽滤、洗涤至中性,再抽滤,真空冷冻干燥后即得李果多酚组合物(微胶囊产品)。
制备的李果提取物微胶囊含有李果总酚22.65wt%;其中结合态多酚占2.72 wt %,杨梅素占1.26 wt %,芦丁占1.19 wt %,檞皮素占0.27 wt %,山奈酚占0.19 wt %,阿魏酸占0.06 wt %,芥子酸占0.11 wt %。
该李果提取物微胶囊对黄嘌呤氧化酶抑制率达47.36%。
实施例2
李果提取物微胶囊的制备方法为:
(1)挑选七八成熟的新鲜胭脂李果实,经干净水清洗,去核,切片,50℃热泵干燥至水份含量小于15wt%,再将干李果片粉碎至粒径小于2mm以下;
(2)李果粉先用超声波提取,以40%(v/v)乙醇作为提取溶剂,提取温度为50℃,李果粉:乙醇=1g:15mL,超声波功率为100W,提取时间为60min,100目筛过滤得李果粗提液Ⅰ,滤渣再用微波萃取;微波萃取参数为:滤渣中加入滤渣质量10倍体积的80%(v/v)乙醇,在微波功率600W下处理5min,采用间断微波处理,微波40s,暂停20s,微波萃取后100目筛过滤得李果粗提液Ⅱ;合并李果粗提液Ⅰ和李果粗提液Ⅱ得到李果粗提液;
(3)李果粗提液经40℃真空浓缩去除乙醇,真空度为0.06MPa;再经AB-8大孔树脂纯化李果提取液,蒸馏水洗树脂,80%(v/v)乙醇溶液解吸洗脱,洗脱液40℃真空浓缩至原洗脱液的50%以下,真空冷冻干燥制备得李果多酚提取物;
(4)以明胶和羧甲基纤维素(CMC)为壁材,采用复凝聚法制备李果多酚微胶囊;将明胶加入水中,在50℃热水浴中以1500r/min转速搅拌15min,制得4wt%的明胶溶液;称取李果多酚提取物后,乙醇溶解,以1500r/min转速边搅拌边加入至明胶溶液中,再将羧甲基纤维素热水溶解缓慢加入,芯材:壁材=l:1,明胶与羧甲基纤维素质量比为6:1;用10%(v/v)冰醋酸调节pH值至4.5,在45℃下恒温反应20min,于冰水浴中搅拌冷却至10℃以下,加入37%(v/v)甲醛溶液固化15min ,用10wt%NaOH 溶液调pH 8,固化l h,抽滤、洗涤至中性,再抽滤,真空冷冻干燥后即得李果多酚提取物(微胶囊产品);
制备的李果提取物微胶囊含有李果总酚48.41wt%,其中,结合态多酚占5.16 wt%,杨梅素占8.64 wt %,芦丁占8.39 wt %,檞皮素占0.91 wt %,山奈酚占0.84 wt %,阿魏酸占0.34 wt %,芥子酸占0.27 wt %。
李果提取物微胶囊对黄嘌呤氧化酶抑制率达81.22%。
实施例3
李果提取物微胶囊的制备方法为:
(1)挑选七八成熟的新鲜芙蓉李果实,经干净水清洗,去核,切片,50℃热泵干燥至水份含量10%,再将干李果片粉碎至粒径小于2mm以下;
(2)李果粉先用超声波提取,以60%(v/v)乙醇作为提取溶剂,提取温度为50℃,李果粉:乙醇=1g:15mL,超声波功率为300W,提取时间为30min,100目筛过滤得李果粗提液Ⅰ,滤渣再用微波萃取;微波萃取参数为:滤渣中加入滤渣质量15倍体积的70%(v/v)乙醇,在微波功率500W下处理6min,采用间断微波处理,微波40s,暂停20s,微波萃取后100目筛过滤得李果粗提液Ⅱ;合并李果粗提液Ⅰ和李果粗提液Ⅱ得到李果粗提液;
(3)李果粗提液经40℃真空浓缩去除乙醇,真空度为0.01MPa;再经AB-8大孔树脂纯化李果提取液,蒸馏水洗树脂,80%(v/v)乙醇溶液解吸洗脱,洗脱液40℃真空浓缩至原洗脱液的50%以下,真空冷冻干燥制备得李果多酚提取物;
(4)以明胶和羧甲基纤维素(CMC)为壁材,采用复凝聚法制备李果多酚微胶囊;将明胶加入水中,在50℃热水浴中以1500r/min转速搅拌15min,制得3wt%的明胶溶液;称取李果多酚提取物后,乙醇溶解,以1500r/min转速边搅拌边加入至明胶溶液中,再将羧甲基纤维素热水溶解缓慢加入,芯材:壁材=l:2,明胶与羧甲基纤维素质量比为5:1;用10%(v/v)冰醋酸调节pH值至4.5,在45℃下恒温反应20min,于冰水浴中搅拌冷却至10℃以下,加入37%(v/v)甲醛溶液固化15min,用10wt%NaOH 溶液调pH 9,固化l h,抽滤、洗涤至中性,再抽滤,真空冷冻干燥后即得李果多酚提取物(微胶囊产品);
制备的李果提取物含有李果总酚30.66wt%;其中,结合态多酚占3.46 wt %,杨梅素占4.54 wt %,芦丁占3.16 wt %,檞皮素占0.46 wt %,山奈酚占0.37 wt %,阿魏酸占0.14 wt %,芥子酸占0.31 wt %。
李果提取物微胶囊对黄嘌呤氧化酶抑制率达69.57%。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (5)
1.一种具有抑制黄嘌呤氧化酶的李果提取物微胶囊,其特征在于:所述的李果提取物微胶囊含有20~50 wt%李果总酚;其中,结合态多酚占2~8 wt %,杨梅素占1~10 wt %,芦丁占1~10 wt %,檞皮素占0.2~1 wt %,山奈酚占0.1~1 wt %,阿魏酸占0.05~0.5 wt%,芥子酸占0.1~0.8 wt %;其制备方法为:将新鲜李果经预处理制得李果粉,然后经超声波-微波分阶段联合提取得到李果粗提液,再经真空浓缩、大孔树脂纯化得到李果多酚提取物,最后经微胶囊化、真空冷冻干燥制备得到李果提取物微胶囊;所述的微胶囊化是以明胶和羧甲基纤维素为复合壁材,以李果多酚提取物为芯材,采用复凝聚法制备李果多酚微胶囊;芯材与壁材的质量比为l:1~3,明胶与羧甲基纤维素的质量比为4~6:1;所述的微胶囊化具体为:将2~4wt%明胶水溶液在50℃热水浴中以1500r/min转速搅拌溶解15min,将乙醇溶解后的李果多酚提取物以1500r/min转速边搅拌边加入至明胶溶液中,再将羧甲基纤维素用水溶解后缓慢加入;用10%(v/v)冰醋酸调节pH值至4.5,在45℃下恒温反应20min,于冰水浴中搅拌冷却至10℃以下,加入37%(v/v)甲醛溶液固化15min,用10wt%NaOH溶液调pH 8~9,固化l h,抽滤、洗涤至中性,再抽滤,真空冷冻干燥后即得李果提取物微胶囊。
2.根据权利要求1所述的具有抑制黄嘌呤氧化酶的李果提取物微胶囊,其特征在于:所述的预处理为:挑选七八成熟的新鲜李果,经纯净水清洗,去核,切片,50℃热泵干燥至水份含量小于15wt%,再将干李果片粉碎至粒径小于2mm以下,制得李果粉。
3.根据权利要求1所述的具有抑制黄嘌呤氧化酶的李果提取物微胶囊,其特征在于:所述的李果包括芙蓉李、胭脂李中的一种。
4.根据权利要求1所述的具有抑制黄嘌呤氧化酶的李果提取物微胶囊,其特征在于:李果粗提液的制备方法为:李果粉先用超声波提取,以40~80 %(v/v)乙醇溶液作为提取溶剂,提取温度为50℃,李果粉:乙醇=1g:15mL,超声波功率为100~400W,提取时间为20~60min,100目筛过滤得李果粗提液Ⅰ;滤渣再用微波萃取,微波萃取参数为:滤渣中加入滤渣质量10~20倍体积的60-80%(v/v)乙醇,在微波功率400-600W下处理5-8min,采用间断微波处理,微波40s,暂停20s,微波萃取后100目筛过滤得李果粗提液Ⅱ;合并李果粗提液Ⅰ和李果粗提液Ⅱ得到李果粗提液。
5.根据权利要求1所述的具有抑制黄嘌呤氧化酶的李果提取物微胶囊,其特征在于:李果多酚提取物的制备方法为:李果粗提液经40℃真空浓缩去除乙醇,真空度为0.01MPa~0.06MPa;再经AB-8大孔树脂纯化李果提取液,蒸馏水洗树脂,80%(v/v)乙醇溶液解吸洗脱,洗脱液40℃真空浓缩,真空冷冻干燥制备得李果多酚提取物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610071936.2A CN105707856B (zh) | 2016-02-02 | 2016-02-02 | 具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610071936.2A CN105707856B (zh) | 2016-02-02 | 2016-02-02 | 具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105707856A CN105707856A (zh) | 2016-06-29 |
CN105707856B true CN105707856B (zh) | 2018-06-22 |
Family
ID=56155498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610071936.2A Active CN105707856B (zh) | 2016-02-02 | 2016-02-02 | 具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105707856B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107616398A (zh) * | 2017-08-18 | 2018-01-23 | 四川岚晟生物科技有限公司 | 一种具有养胃健脾的固体饮料及其制备方法 |
CN107568547A (zh) * | 2017-08-18 | 2018-01-12 | 四川岚晟生物科技有限公司 | 一种具有宁心安神的固体饮料及其制备方法 |
CN116210900B (zh) * | 2022-12-29 | 2024-01-30 | 抱朴生命科技(广州)有限公司 | 一种调节黄嘌呤氧化酶活性的植物多酚缓释组合物及其精准营养物和制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003000196A (ja) * | 2001-04-16 | 2003-01-07 | Asahi Soft Drinks Co Ltd | 糖尿病の治療・予防用食品 |
JP2007159572A (ja) * | 2005-11-21 | 2007-06-28 | Riken Vitamin Co Ltd | 飲料用ビタミンe含有組成物 |
CN101428069A (zh) * | 2008-12-08 | 2009-05-13 | 广东省农业科学院蚕业与农产品加工研究所 | 一种桑叶多酚的制备方法及其微胶囊和应用 |
CN104886577A (zh) * | 2015-06-16 | 2015-09-09 | 福建省农业科学院农业工程技术研究所 | 一种李果多酚的制备方法 |
-
2016
- 2016-02-02 CN CN201610071936.2A patent/CN105707856B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003000196A (ja) * | 2001-04-16 | 2003-01-07 | Asahi Soft Drinks Co Ltd | 糖尿病の治療・予防用食品 |
JP2007159572A (ja) * | 2005-11-21 | 2007-06-28 | Riken Vitamin Co Ltd | 飲料用ビタミンe含有組成物 |
CN101428069A (zh) * | 2008-12-08 | 2009-05-13 | 广东省农业科学院蚕业与农产品加工研究所 | 一种桑叶多酚的制备方法及其微胶囊和应用 |
CN104886577A (zh) * | 2015-06-16 | 2015-09-09 | 福建省农业科学院农业工程技术研究所 | 一种李果多酚的制备方法 |
Non-Patent Citations (1)
Title |
---|
黄酮类化合物防治高尿酸血症和痛风的研究进展;夏道宗等;《中国药学杂志》;20090522;第44卷(第10期);对比文件2第721页左栏1.1小节以及右栏表1 * |
Also Published As
Publication number | Publication date |
---|---|
CN105707856A (zh) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101605068B1 (ko) | 마이크로파 화학 처리에 기반한 고등식물 및 곰팡이 다당류의 추출 공정 | |
CN105707856B (zh) | 具有抑制黄嘌呤氧化酶的李果提取物微胶囊及其制备方法 | |
CN105816518B (zh) | 一种核桃青皮酚类天然抗氧化剂及其制备方法和应用 | |
CN104341431A (zh) | 一种从石榴皮中提取鞣花酸的方法 | |
CN106822214A (zh) | 一种橄榄叶提取物制备方法 | |
CN108159100A (zh) | 一种从太行菊中提取太行菊总黄酮的方法 | |
CN109082723B (zh) | 一种沙棘叶纤维素纤维 | |
CN103463160A (zh) | 一种高含量菊花总黄酮的制备方法 | |
CN107177579B (zh) | 一种利用蒜片加工废水制备蒜氨酸酶、大蒜辣素和大蒜多糖的方法 | |
CN102040665A (zh) | 海参多糖的提取方法 | |
CN106632208A (zh) | 一种紫薯中花青素的提取方法 | |
CN101863807B (zh) | 一种大蒜提取物的制造方法 | |
CN101433322B (zh) | 一种富含花青素的功能食品及其制备方法 | |
CN110639226A (zh) | 一种脱除蜂胶中杂质的方法 | |
CN109846932A (zh) | 一种桑葚渣降血糖活性成分的提取纯化及制备技术 | |
CN111196796A (zh) | 一种从桑寄生中提取槲皮素的制备方法 | |
CN101823955B (zh) | 一种从玉米皮中提取阿魏酸的方法 | |
CN108570091A (zh) | 一种薯蓣皂苷的制备方法 | |
CN108403732A (zh) | 一种青梅总提取物的工业生产方法 | |
CN108434171A (zh) | 一种预防化学性肝损伤的慈姑多糖组合物及其制备方法 | |
CN104800272A (zh) | 苦瓜皂甙提取新技术 | |
CN107050249A (zh) | 一种紫山药中植物多酚的提取方法 | |
CN106632549B (zh) | 一种离子液体提取柚子皮中柚皮甙的方法 | |
CN111329888A (zh) | 一种三七花片及其生产制备工艺 | |
CN104983841A (zh) | 一种樱桃提取物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |